Articles from Kallyope

Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today the Company announced that it will present results from a Phase 2b dose-ranging study of its novel therapy elismetrep in an oral presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting being held April 18-22, 2026 in Chicago, IL. Elismetrep is the only TRPM8 migraine-associated channel blocker (MACB) in late-stage clinical studies for the treatment of migraine.

Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally, announced the Company’s strategic priorities for 2026. Kallyope’s lead programs target previously unknown drivers of disease in neural signaling pathways.

Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for health challenges faced by hundreds of millions of people globally, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference to be held January 12-15 in San Francisco, CA.

Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for migraine and metabolism, today announced positive results from a Phase 2b study of the company’s lead candidate elismetrep, an oral Transient Receptor Potential Melastatin 8 (TRPM8) antagonist being studied for the acute treatment of migraine. In the study, elismetrep delivered a favorable clinical profile through its novel mechanism, supporting its potential as a new therapeutic option for the large number of patients who are suffering from the debilitating effects of migraine.

Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of obesity.